Literature DB >> 31673543

Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein.

Edoardo G Giannini1, Franco Trevisani2.   

Abstract

Entities:  

Year:  2019        PMID： 31673543      PMCID： PMC6791995          DOI： 10.21037/hbsn.2019.04.19

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  19 in total

1.  The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.

Authors:  Angelo Sangiovanni; Gian Maria Prati; Pierangelo Fasani; Guido Ronchi; Raffaella Romeo; Matteo Manini; Ersilio Del Ninno; Alberto Morabito; Massimo Colombo
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

2.  Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status.

Authors:  Yun-feng Shan; Yuan-lan Huang; Yuan-kang Xie; Yan-he Tan; Bi-Cheng Chen; Men-tao Zhou; Hong-qi Shi; Zheng-ping Yu; Qi-tong Song; Qi-yu Zhang
Journal:  Med Oncol       Date:  2010-06-23       Impact factor: 3.064

3.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Authors:  Ghassan K Abou-Alfa; Tim Meyer; Ann-Lii Cheng; Anthony B El-Khoueiry; Lorenza Rimassa; Baek-Yeol Ryoo; Irfan Cicin; Philippe Merle; YenHsun Chen; Joong-Won Park; Jean-Frederic Blanc; Luigi Bolondi; Heinz-Josef Klümpen; Stephen L Chan; Vittorina Zagonel; Tiziana Pressiani; Min-Hee Ryu; Alan P Venook; Colin Hessel; Anne E Borgman-Hagey; Gisela Schwab; Robin K Kelley
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

Review 4.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

5.  Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Authors:  Michael Bitzer; Marius Horger; Edoardo G Giannini; Tom M Ganten; Marcus A Wörns; Jens T Siveke; Matthias M Dollinger; Guido Gerken; Max E Scheulen; Henning Wege; Vittorina Zagonel; Umberto Cillo; Franco Trevisani; Armando Santoro; Vincenzo Montesarchio; Nisar P Malek; Julia Holzapfel; Thomas Herz; Astrid S Ammendola; Stefano Pegoraro; Bernhard Hauns; Anna Mais; Ulrich M Lauer; Stefan W Henning; Bernd Hentsch
Journal:  J Hepatol       Date:  2016-03-04       Impact factor: 25.083

6.  Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.

Authors:  Edoardo G Giannini; Giorgio Sammito; Fabio Farinati; Francesca Ciccarese; Anna Pecorelli; Gian Lodovico Rapaccini; Mariella Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Giuseppe Cabibbo; Martina Felder; Antonio Gasbarrini; Rodolfo Sacco; Francesco Giuseppe Foschi; Gabriele Missale; Filomena Morisco; Gianluca Svegliati Baroni; Roberto Virdone; Franco Trevisani
Journal:  Cancer       Date:  2014-04-10       Impact factor: 6.860

7.  Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma.

Authors:  Luigi Bolondi; Umberto Cillo; Massimo Colombo; Antonio Craxì; Fabio Farinati; Edoardo G Giannini; Rita Golfieri; Massimo Levrero; Antonio Daniele Pinna; Fabio Piscaglia; Giovanni Raimondo; Franco Trevisani; Raffaele Bruno; Paolo Caraceni; Alessia Ciancio; Barbara Coco; Mirella Fraquelli; Maria Rendina; Giovanni Squadrito; Pierluigi Toniutto
Journal:  Dig Liver Dis       Date:  2013-02-23       Impact factor: 4.088

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

Review 10.  Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?

Authors:  Edoardo G Giannini; Alessandro Cucchetti; Virginia Erroi; Francesca Garuti; Federica Odaldi; Franco Trevisani
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.